A&D Pharma Holdings posts a 90 percent higher net profit in H1 2010, announces expansion plans

Pharmaceutical group A&D Pharma Holdings N.V., the Dutch holding company of A&D Pharma Holdings S.R.L. posted a EUR 24.7 million operating profit for the first half of the year, 45 percent higher on the same period last year, and a 90 percent higher net profit (EUR 17.5 million). According to the company’s preliminary data, its consolidated sales went up by 30 percent (EUR) and 28 percent (RON).

The company’s retail division, pharmacy chain Sensiblu, registered a 37 percent sales increase (EUR 119.5 million) and a 4 times higher operating profit (EUR 6.6 million) for the same time period, said company representatives. “We are satisfied with the results of all our business lines”, said Robert Popescu, the company’s CEO. He added that in the light of recent macroeconomic and legal changes A&D Pharma remains cautious when talking about the future of the local pharmaceutical market.

“We are a sound business with balanced financial results. We have consolidated our leader position on the Romanian market and adjusted our operating profit. We have also recently announced expansion plans to five other central and south-eastern European countries following some acquisitions”, Popescu concluded.

At the beginning of July company representatives announced the acquisition of Arishop Pharma AD and all its subsidiaries in Bulgaria, Ozone Laboratoires Polska and Ozone Laboratories Polska Services in Poland, Ozone Laboratories Magyarorszag Kft.in Hungary, Ozone Laboratories Slovakia s.r.o. in Slovakia si Ozone Laboratories Czech Republic s.r.o. for EUR 19.1 million.

Simona Bazavan

Read more about

AROBS targets a consolidated turnover of approximately RON 500 million in 2024

read more

Pharmaceutical group A&D Pharma Holdings N.V., the Dutch holding company of A&D Pharma Holdings S.R.L. posted a EUR 24.7 million operating profit for the first half of the year, 45 percent higher on the same period last year, and a 90 percent higher net profit (EUR 17.5 million). According to the company’s preliminary data, its consolidated sales went up by 30 percent (EUR) and 28 percent (RON).

 

The company’s retail division, pharmacy chain Sensiblu, registered a 37 percent sales increase (EUR 119.5 million) and a 4 times higher operating profit (EUR 6.6 million) for the same time period, said company representatives. “We are satisfied with the results of all our business lines”, said Robert Popescu, the company’s CEO. He added that in the light of recent macroeconomic and legal changes A&D Pharma remains cautious when talking about the future of the local pharmaceutical market.

 

“We are a sound business with balanced financial results. We have consolidated our leader position on the Romanian market and adjusted our operating profit. We have also recently announced expansion plans to five other central and south-eastern European countries following some acquisitions”, Popescu concluded.

 

At the beginning of July company representatives announced the acquisition of Arishop Pharma AD and all its subsidiaries in Bulgaria, Ozone Laboratoires Polska and

Ozone Laboratories Polska Services in Poland, Ozone Laboratories Magyarorszag Kft.in Hungary, Ozone Laboratories Slovakia s.r.o. in Slovakia si Ozone Laboratories Czech Republic s.r.o. for EUR 19.1 million.